Drugmaker GSK raises outlook and looks to new medicines to fuel growth

The drugmaker has been under pressure to replenish its pipeline as it faces patent expirations for products including one of its key HIV drugs.

Drugmaker GSK raised its guidance for the year after a strong start to 2023, as it prepares to begin selling one of the first vaccines to prevent a common respiratory virus.

Sales will likely increase by as much as 10% and earnings per share by as much as 17% this year, the firm said, helped by the success of its blockbuster vaccine for shingles.